Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing therapies in the disease areas of immunology, inflammation and oncology in the United States. It is developing GB001, an oral prostaglandin D2 receptor 2 antagonist, which is in a phase IIb clinical trial for the treatment of moderate to severe eosinophilic asthma; in a phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in the phase 2 clinical trial in patients with chronic spontaneous urticaria. The company is also developing GB002, an orally inhaled, small-molecule, platelet-derived growth factor receptor kinase inhibitor, in a phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule gut-targeted system in a Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease; and GB1275, an oral small molecule modulator of CD11b in a phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related supporting compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was previously known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California. CD11b modulator in phase 1/2 clinical trial for the treatment of certain types of solid tumors. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related supporting compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was previously known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California. CD11b modulator in phase 1/2 clinical trial for the treatment of certain types of solid tumors. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related supporting compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds.
How to buy Gossamer Bio (GOS) shares | Tutorial
Are you interested in acquiring Gossamer Bio (GOS) shares on Nasdaq from Spain and through an officially regulated broker? Are you interested in investing your bank profits and having interests in the stock market? Today I am going to show you how you can register with degiro , a reliable German investment broker with very low commissions, and how you will be able to buy shares of the company Gossamer Bio, Inc. (GOS) (GOS) quickly. And simple.
The step by step is intuitive :
- The first step is that we will create an account in degiro, a broker platform where we will be able to buy shares of the company Gossamer Bio, Inc. (GOS) (GOSS).
- In this step we will transfer euros and be able to make the 1st investment.
- When we see the funds in our account, we will locate the Gossamer Bio company with the TICKER, which is GOSS.
- Then we must adjust the number of shares we want, the purchase price and type of order.
It is possible that this summary has not been a bit detailed for you, therefore I am going to show you the process with images:
How to register at the broker DEGIRO.
First of all we must register in Degiro through the following link :
It will require an email, a username and a password to access, and then we must continue from the link that they have sent us by email address.
Next, DeGiro will require information of interest in order to certify our identity card . We must have at hand our passport, ID or driving license, your cell phone and the account number that we will use to make our 1st deposit. If you don’t know what method this format is, you can check this simple guide article that we did from Educacep .
Once our account is authorized we will be able to enter money from the Deposit/Withdraw tab. We have the possibility of making a transfer that will take two to three days, or being able to make the deposit quickly using Sofort, a 100% secure and 100% reliable payment gateway.
How to buy Gossamer Bio (GOS) shares through DEGIRO
Once we have the capital we will be able to acquire our 1st share. You can press the «Place Order» button in the right corner or select the Degiro browser and put the ticker. In the following screenshot you will find that I have used the Amazon Ticker but you should type (GOSS), the Gossamer Bio ticker. As it is an action, we will see that the related results are listed and there we will discover to find Gossamer Bio. The most essential thing is that the ticker, the name of the company and the market in which it is listed coincide. Amazon is listed on Nasdaq (NDQ) and in your case Gossamer Bio, Inc. (GOSS) is listed on Nasdaq. This step is essential so make no mistake.
When developing the order we will have to pay attention to what I am going to explain to you . We have the possibility to carry out a limit or market order. Imagine that you want to buy a share of Gossamer Bio, but its price today is more prominent. With this limit order we will introduce the value at which we want to make the acquisition and until there are no shares selling at that value, the acquisition of the share will not be executed. With a market order DEGIRO will buy the number of shares we have indicated at the current selling price, which would be very close to the current listing price.
In one case or another it is very important that you look at the type of classification: permanent or daily . For example, in Spain, the stock market is in the morning and until 1:00 p.m., and in the US it coincides with the afternoon schedule in Spain. If an order is permanent, it will continue until the moment it can be executed, but if you opt for the «of the day» option, at the moment the trading day ends, if it had not been carried out, it will be removed from your Activity – Pending Orders.
I hope that this short text will help you to invest in Gossamer Bio. Thank you.
|Name||Title||Salary||exercised||Year of birth|
|Mr Faheem Hasnain||Co-Founder, Director, President and President||702.68k||N/A||1958|
|Mr. Bryan Giraudo||CFO||593.07k||N/A||1976|
|Mr Christian Waage||Exec. Vice President, General Counsel and Sec.||568.46k||N/A||1967|
|Dr. Laura L. Carter||Scientific Director||N/A||N/A||1967|
|Mrs Deanna Weber||Senior Vice President of HR||N/A||N/A||N/A|
|Dr Richard Aranda MD||Medical director||N/A||N/A||N/A|
|Mrs. Caryn L. Peterson||Exec. Vice President of Regulatory Affairs||N/A||N/A||1959|
|Dr. Larry Zisman MD||Sr. Director of Clinical Development.||N/A||N/A||N/A|
|Robert F. Roscigno, MD||Vice President of Clinical Development.||N/A||N/A||1966|
|Mr Mario Orlando||Vice President of New Product Business Planning||N/A||N/A||N/A|
Recent events of :
We have no recent events for this company.